Pharmacokinetic Study of Albuvirtide and Lopinavir/Ritonavir in HIV-infected Patients
Latest Information Update: 24 Apr 2016
Price :
$35 *
At a glance
- Drugs Labuvirtide (Primary) ; Lopinavir/ritonavir
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors Frontier Biotechnologies
- 03 Feb 2014 Status changed from recruiting to completed as reported by the Chinese Clinical Trial Register.
- 24 Apr 2013 New trial record